<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36288714</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2.</ArticleTitle><Pagination><StartPage>111508</StartPage><MedlinePgn>111508</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2022.111508</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(22)01358-4</ELocationID><Abstract><AbstractText>Mutations in the ataxin-2 gene (ATXN2) cause the neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia type 2 (SCA2). A therapeutic strategy using antisense oligonucleotides targeting ATXN2 has entered clinical trial in humans. Additional ways to decrease ataxin-2 levels could lead to cheaper or less invasive therapies and elucidate how ataxin-2 is normally regulated. Here, we perform a genome-wide fluorescence-activated cell sorting (FACS)-based CRISPR-Cas9 screen in human cells and identify genes encoding components of the lysosomal vacuolar ATPase (v-ATPase) as modifiers of endogenous ataxin-2 protein levels. Multiple FDA-approved small molecule v-ATPase inhibitors lower ataxin-2 protein levels in mouse and human neurons, and oral administration of at least one of these drugs-etidronate-is sufficient to decrease ataxin-2 in the brains of mice. Together, we propose v-ATPase as a drug target for ALS and SCA2 and demonstrate the value of FACS-based screens in identifying genetic-and potentially druggable-modifiers of human disease proteins.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Garam</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Neurosciences Interdepartmental Program, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>Jacob A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Neurosciences Interdepartmental Program, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeynaems</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakraborty</LastName><ForeName>Meenakshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couthouis</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tassoni-Tsuchida</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Caitlin M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassik</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: agitler@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04494256</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS116208</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK116074</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025212</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS125681</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG064690</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG047126</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097263</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D025262">Vacuolar Proton-Translocating ATPases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>M2F465ROXU</RegistryNumber><NameOfSubstance UI="D012968">Etidronic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025262" MajorTopicYN="Y">Vacuolar Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012968" MajorTopicYN="N">Etidronic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="Y">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CP: Neuroscience</Keyword><Keyword MajorTopicYN="N">FACS</Keyword><Keyword MajorTopicYN="N">SCA2</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">ataxin-2</Keyword><Keyword MajorTopicYN="N">bisphosphonate</Keyword><Keyword MajorTopicYN="N">etidronate</Keyword><Keyword MajorTopicYN="N">genetic screens</Keyword><Keyword MajorTopicYN="N">small-molecule therapy</Keyword><Keyword MajorTopicYN="N">v-ATPase</Keyword></KeywordList><CoiStatement>Declaration of interests A.D.G. is a scientific founder of Maze Therapeutics. Stanford University has filed a provisional patent (63/286,436) on methods described in this manuscript for treatment of neurodegenerative diseases through the inhibition of ataxin-2.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36288714</ArticleId><ArticleId IdType="mid">NIHMS1845179</ArticleId><ArticleId IdType="pmc">PMC9664452</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.111508</ArticleId><ArticleId IdType="pii">S2211-1247(22)01358-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altman RD, Johnston CC, Khairi MR, Wellman H, Serafini AN, and Sankey RR (1973). Influence of disodium etidronate on clinical and laboratory manifestations of Paget&#x2019;s disease of bone (osteitis deformans). N. Engl. J. Med. 289, 1379&#x2013;1384. 10.1056/NEJM197312272892601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197312272892601</ArticleId><ArticleId IdType="pubmed">4201876</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, Hart MP, and Gitler AD (2011). TDP-43 toxicity in yeast. Methods 53, 238&#x2013;245. 10.1016/j.ymeth.2010.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2010.11.006</ArticleId><ArticleId IdType="pmc">PMC3073690</ArticleId><ArticleId IdType="pubmed">21115123</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling S-C, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, Kordasiewicz HB, McAlonis-Downes M, Platoshyn O, Parone PA, et al. (2013). ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. USA 110, E736&#x2013;E745. 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367&#x2013;371. 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Kordasiewicz HB, and Cleveland DW (2021). Antisense drugs make sense for neurological diseases. Annu. Rev. Pharmacol. Toxicol. 61, 831&#x2013;852. 10.1146/annurev-pharmtox-010919-023738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010919-023738</ArticleId><ArticleId IdType="pmc">PMC8682074</ArticleId><ArticleId IdType="pubmed">33035446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan C-Y, Prudom C, Raines SM, Charkhzarrin S, Melman SD, De Haro LP, Allen C, Lee SA, Sklar LA, and Parra KJ (2012). Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p). J. Biol. Chem. 287, 10236&#x2013;10250. 10.1074/jbc.M111.321133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.321133</ArticleId><ArticleId IdType="pmc">PMC3323027</ArticleId><ArticleId IdType="pubmed">22215674</ArticleId></ArticleIdList></Reference><Reference><Citation>David P, Nguyen H, Barbier A, and Baron R (1996). The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J. Bone Miner. Res. 11, 1498&#x2013;1507. 10.1002/jbmr.5650111017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.5650111017</ArticleId><ArticleId IdType="pubmed">8889850</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, Silsby M, Menon P, van den Bos M, Halliday GM, et al. (2020). TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry 92, 86&#x2013;95. 10.1136/jnnp-2020-322983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21. 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake MT, Clarke BL, and Khosla S (2008). Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032&#x2013;1045. 10.4065/83.9.1032.</Citation><ArticleIdList><ArticleId IdType="doi">10.4065/83.9.1032</ArticleId><ArticleId IdType="pmc">PMC2667901</ArticleId><ArticleId IdType="pubmed">18775204</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075. 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, and Lee VM-Y (2004). Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10, 1055&#x2013;1063. 10.1038/nm1113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1113</ArticleId><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, Strider J, Carter D, Taylor-Reinwald L, Forman MS, Goate AM, and Cairns NJ (2009). VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. J. Biol. Chem. 284, 12384&#x2013;12398. 10.1074/jbc.M900992200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M900992200</ArticleId><ArticleId IdType="pmc">PMC2673306</ArticleId><ArticleId IdType="pubmed">19237541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart MP, and Gitler AD (2012). ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J. Neurosci. 32, 9133&#x2013;9142. 10.1523/JNEUROSCI.0996-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0996-12.2012</ArticleId><ArticleId IdType="pmc">PMC3418890</ArticleId><ArticleId IdType="pubmed">22764223</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM,Weber C, Mandel JL, Cancel G, Abbas N, et al. (1996). Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 14, 285&#x2013;291. 10.1038/ng1196-285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1196-285</ArticleId><ArticleId IdType="pubmed">8896557</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, and Gitler AD (2020). ALS genetics: gains, losses, and implications for future therapies. Neuron 108, 822&#x2013;842. 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H-J, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM-Y, Finkbeiner S, Gitler AD, and Bonini NM (2014). Therapeutic modulation of eIF2&#x3b1; phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet. 46, 152&#x2013;160. 10.1038/ng.2853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2853</ArticleId><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer NJ, Haney MS, Morgens DW, Jovi&#x10d;i&#x107; A, Couthouis J, Li A, Ousey J, Ma R, Bieri G, Tsui CK, et al. (2018). CRISPR&#x2013;Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat. Genet. 50, 603&#x2013;612. 10.1038/s41588-018-0070-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0070-7</ArticleId><ArticleId IdType="pmc">PMC5893388</ArticleId><ArticleId IdType="pubmed">29507424</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, and Gitler AD (2013). Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201, 361&#x2013;372. 10.1083/jcb.201302044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201302044</ArticleId><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, and Anders S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, Al-Ramahi I, Valencia A, Wang Q, Berenshteyn F, Yang H, Gallego-Flores T, Ichcho S, Lacoste A, Hild M, et al. (2013). Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. Nat. Neurosci. 16, 562&#x2013;570. 10.1038/nn.3367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3367</ArticleId><ArticleId IdType="pubmed">23525043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, Briner A, Rodriguez CM, Guo C, Akiyama T, et al. (2022). TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 603, 124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxson ME, and Grinstein S (2014). The vacuolar-type H+-ATPase at a glance - more than a proton pump. J. Cell Sci. 127, 4987&#x2013;4993. 10.1242/jcs.158550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.158550</ArticleId><ArticleId IdType="pubmed">25453113</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgens DW, Deans RM, Li A, and Bassik MC (2016). Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nat. Biotechnol. 34, 634&#x2013;636. 10.1038/nbt.3567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3567</ArticleId><ArticleId IdType="pmc">PMC4900911</ArticleId><ArticleId IdType="pubmed">27159373</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgens DW, Wainberg M, Boyle EA, Ursu O, Araya CL, Tsui CK, Haney MS, Hess GT, Han K, Jeng EE, et al. (2017). Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat. Commun. 8, 15178. 10.1038/ncomms15178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15178</ArticleId><ArticleId IdType="pmc">PMC5424143</ArticleId><ArticleId IdType="pubmed">28474669</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretzschmar HA, Kimonis VE, and Forman MS (2007). TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J. Neuropathol. Exp. Neurol. 66, 152&#x2013;157. 10.1097/nen.0b013e31803020b9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31803020b9</ArticleId><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133. 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Al-Ramahi I, Tan Q, Mollema N, Diaz-Garcia JR, Gallego-Flores T, Lu H-C, Lagalwar S, Duvick L, Kang H, et al. (2013). RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 498, 325&#x2013;331. 10.1038/nature12204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12204</ArticleId><ArticleId IdType="pmc">PMC4020154</ArticleId><ArticleId IdType="pubmed">23719381</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, LopesCendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes A, et al. (1996). Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 14, 269&#x2013;276. 10.1038/ng1196-269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1196-269</ArticleId><ArticleId IdType="pubmed">8896555</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez CM, Bechek SC, Jones GL, Nakayama L, Akiyama T, Kim G, Solow-Cordero DE, Strittmatter SM, and Gitler AD (2022). Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2. Cell Rep. 41. 10.1101/2021.12.20.473562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.20.473562</ArticleId><ArticleId IdType="pmc">PMC9664481</ArticleId><ArticleId IdType="pubmed">36288715</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A, Kontarakis Z, Gerri C, Nolte H, H&#xf6;lper S, Kr&#xfc;ger M, and Stainier DYR (2015). Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature 524, 230&#x2013;233. 10.1038/nature14580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14580</ArticleId><ArticleId IdType="pubmed">26168398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux MWC, V&#xe1;zquez-V&#xe9;lez GE, Al-Ramahi I, Jeong H-H, Baji&#x107; A, Revelli J-P, Ye H, Phan ET, Deger JM, Perez AM, et al. (2018). A druggable genome screen identifies modifiers of &#x3b1;-synuclein levels via a tiered cross-species validation approach. J. Neurosci. 38, 9286&#x2013;9301. 10.1523/JNEUROSCI.0254-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0254-18.2018</ArticleId><ArticleId IdType="pmc">PMC6199406</ArticleId><ArticleId IdType="pubmed">30249792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, Wakisaka A, Tashiro K, Ishida Y, Ikeuchi T, et al. (1996). Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet. 14, 277&#x2013;284. 10.1038/ng1196-277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1196-277</ArticleId><ArticleId IdType="pubmed">8896556</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, and Pulst SM (2017). Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544, 362&#x2013;366. 10.1038/nature22044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22044</ArticleId><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="pubmed">28405024</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR, and Pulst SM (2018). Spinocerebellar ataxia type 2. Adv. Exp. Med. Biol. 1049, 175&#x2013;195. 10.1007/978-3-319-71779-1_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-71779-1_8</ArticleId><ArticleId IdType="pubmed">29427103</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GDJ, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, and Kimonis VE (2004). Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377&#x2013;381. 10.1038/ng1332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1332</ArticleId><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick-de Groote C, Van Broeckhoven C, and Kumar-Singh S (2010). TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA 107, 3858&#x2013;3863. 10.1073/pnas.0912417107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912417107</ArticleId><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J-A, Frick L, Scheidmann MC, Trevisan C, Dhingra A, Spinelli A, Wu Y, Yao L, Vena DL, De Cecco E, et al. (2022). Robust and versatile arrayed libraries for human genome-wide CRISPR activation, deletion and silencing. Preprint at bioRxiv. 10.1101/2022.05.25.493370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.25.493370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, et al. (2018). Stress granule assembly disrupts nucleocytoplasmic transport. Cell 173, 958&#x2013;971.e17. 10.1016/j.cell.2018.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.025</ArticleId><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>